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Aims Severe COVID-19 has been anecdotally associated with high insulin 
requirements. It has been proposed that this may be driven by a direct diabetogenic 
effect of the virus that is unique to SARS-CoV-2, but evidence to support this is limited. 
To explore this, we compared insulin requirements in patients with severe COVID-19 
and non-COVID-19 viral pneumonitis. 
Methods Retrospective cohort study of patients with severe COVID-19 admitted to 
our intensive care unit between March and June 2020. A historical control cohort of 
non-COVID-19 viral pneumonitis patients was identified from routinely collected audit 
data.  
Results Insulin requirements were similar in patients with COVID-19 and non-COVID-
19 viral pneumonitis after adjustment for pre-existing diabetes and severity of 
respiratory failure.  
Conclusions In this single center study, we could not find evidence of a unique 
diabetogenic effect of COVID-19. We suggest that high insulin requirements in this 
disease relate to its propensity to cause severe respiratory failure in patients with pre-
existing metabolic disease. 









There is emerging interest in the effect of COVID-19 on glucose homeostasis, with 
some suggesting that COVID-19 may be a uniquely diabetogenic virus [1]. 
Observations advanced to support this hypothesis include anecdotal reports of high 
insulin requirements in patients with severe COVID-19 [2-4]. However, to date there 
has been no longitudinal study of patients with COVID-19 to empirically assess insulin 
requirements. We sought to address this deficiency by comparing insulin requirements 
in patients admitted to intensive care with severe COVID-19 to a historical control 
group with severe non-COVID-19 viral pneumonitis.   
 
Research Design and Methods  
 
Case Identification 
Patients admitted to ICU in Addenbrooke’s Hospital, Cambridge with a positive SARS-
CoV-2 test were identified. Patients were deemed to have COVID-19 pneumonitis and 
included in the study if they were SARS-CoV-2 positive and were treated for 
respiratory failure that was attributed to COVID-19 pneumonitis by the treating team 
during their ICU stay. 
 
The non-COVID-19 viral pneumonitis cohort was identified from the ICU’s routinely 
collected audit data from 2014 to 2019. Patients admitted with a diagnosis of viral 
pneumonia recorded as their primary, secondary or ultimate reason for admission to 
intensive care were included in the analysis.  
All eligible participants were included. 
 
Data Collection 
Data collection was undertaken manually from electronic medical records by trained, 
clinical investigators. Blood glucose data was collected using proprietary analytics 
software, Qlikview. Further detail is available in the supplementary appendix. 
 
Matching 
Patients admitted with COVID-19 pneumonitis were matched according to diabetes 
status and level of respiratory support received in a 1:1 ratio to a historical control 
cohort of patients admitted to ICU with non-COVID-19 viral pneumonitis. Further data 
is available in the supplementary appendix.  
 
Statistical Analysis 
Details of the statistical analysis are available in the supplementary appendix.  
 
Results 
During the study period March to June 2020 we identified 92 patients treated for severe 
COVID-19 within our intensive care unit (Supplementary Appendix Figure 1). In 
univariate linear regression analysis, BMI, pre-existing Type 1 or Type 2 Diabetes and 
severity of respiratory failure assessed by ordinal scale (0 – self ventilating, 1- 
mechanical ventilation, 2 – neuromuscular blockade, 3 – nebulized epoprostenol, 4 – 
prone ventilation, 5 – extracorporeal membrane oxygenation) were all associated with 
insulin dose when analyzed by the average dose across the whole ICU stay or by the 
highest cumulative insulin dose over a 24 hour period  (Supplementary Appendix, 
Table 1).  
 
To determine if the observed insulin requirements were a unique feature of COVID-19 
we examined insulin requirements in 46 patients admitted to our ICU with a diagnosis 
of non-COVID-19 viral pneumonitis between 2014 and 2019. 89% of the non-COVID-
19 cohort had a confirmed viral isolate consistent with viral pneumonia. 5 patients 
included in the analysis did not have any relevant positive virology related to their ICU 
admission but were diagnosed with viral pneumonitis on clinical grounds while 2 
patients had more than 1 virus identified that could have explained their symptoms 
(Supplementary Appendix, Table 2 for a breakdown of viral isolates). Insulin 
requirements were higher in patients with COVID-19 versus non-COVID-19 viral 
pneumonitis while mean glycemic indices were comparable in both groups (Figure 1A-
B and Supplementary Appendix Figure 2A-B). However, the groups were poorly 
balanced with respect to diabetes status and requirement for respiratory salvage 
therapies (Supplementary Appendix, Table 3), multiple regression analysis did not 
identify any association between COVID-19 and insulin dose after adjustment for pre-
existing diabetes and severity of respiratory failure (Table 1).  Whilst severity of 
respiratory failure was independently associated with insulin requirement, we did not 
find a similar relationship for vasopressor use or APACHE II score (data not shown). 
When COVID-19 and non-COVID-19 viral pneumonitis patients were matched (1:1, N 
= 36 per group) by the level of respiratory support required and pre-existing diabetes 
status, the proportion of patients requiring insulin (COVID-19: 41%, non-COVID-19: 
49%) and insulin dose was similar in those who were treated with insulin (Figure 1C-
D and Supplementary Figure 2C-D). We acknowledge that diabetes is a heterogenous 
condition with different intensity of treatment and adequacy of glycaemic control and 
controlling for it as a single variable is limited. However, the number of patients with 
type 1 diabetes in COVID-19 and non-COVID-19 were the same and the treatments 
used in Type 2 Diabetes COVID-19 and non-COVID-19 viral pneumonitis are not 
dissimilar (Supplementary Table 4). Unfortunately, a large proportion of patients in our 
study did not have pre-morbid HbA1c values on records at our institution therefore 
precluding meaningful comparison of pre-morbid glycaemic control.  
 
Finally, we sought to determine if the insulin requirements observed in patients with 
COVID-19 resolved in convalescence. Diabetes therapies used in patients with 
COVID-19 and non-COVID-19 viral pneumonitis are summarized in Supplementary 
Table 4. We had information on discharge medication in 61/62 patients who survived 
to hospital discharge. Of these patients 39 required insulin while in ICU but on 
discharge only 5 patients were discharged from hospital on subcutaneous insulin, 4 of 
whom were on insulin prior to admission. The one patient commenced on insulin had 
Type 2 Diabetes prior to admission managed with oral therapy, insulin was 
discontinued soon after discharge when they were readmitted with hypoglycemia. 
There was no initiation or escalation in oral hypoglycemic agents in the cohort, 
however we cannot comment on the adequacy of glycemic control. Similar findings 
from a smaller cohort have recently been reported [3].  
Discussion 
We report here, to the best of our knowledge, the first longitudinal assessment of 
glycemia and insulin requirements in patients who are critically ill with COVID-19. Our 
data suggest that high insulin requirements observed in patients with severe COVID-
19 is related to the severity of respiratory failure and pre-existing diabetes mellitus 
rather than a direct diabetogenic effect of SARS-CoV-2. Therefore, there is currently 
no rationale to adopt novel strategies or different glycemic thresholds to manage 
hyperglycemia in COVID-19 compared to other viral pneumonias and several reviews 
have outlined practical approaches to the management of hyperglycaemia in COVID-
19 [2, 4, 5]. Moreover, the comparable insulin requirements in COVID-19 and non-
COVID-19 viral pneumonitis when severity of illness and pre-existing diabetes are 
accounted for argue against a direct action of SARS-CoV-2 on the pancreatic b-cell 
as the likely cause of hyperglycaemia in COVID-19, as has been suggested previously 
[6]. In addition, our data suggest that the hyperglycemia observed in patients with 
COVID-19 is transient and resolves in convalescence and leads us to caution studies 
describing new-onset diabetes in patients with COVID-19 based on cross-sectional 
blood glucose measurements [7].  
Our findings are complementary to a recent analysis that examined time in target 
glucose range in patients admitted to ICU with COVID-19. The authors found that 
ventilator use, neuromuscular blockade and use of high-flow nasal oxygen all 
predicted poor glycaemic control [8]. Interestingly, this study compared glycaemia and 
insulin requirements in 93 COVID-19 patients to all (N = 469) contemporaneous ICU 
admissions (for any reason) without COVID-19 and found that COVID-19 patients had 
poorer glycaemic control and higher insulin requirements. However, the COVID-19 
group required much more respiratory support compared to the non-COVID-19 group 
and the authors did not make any attempt to adjust for this difference.  
 
While preparing our paper for publication two separate analyses have suggested that 
insulin therapy in hospital may be associated with increased mortality in patients with 
Type 2 Diabetes [9, 10]. One of these reports has been widely interpreted as 
supporting the supposition that insulin therapy is detrimental in COVID-19 [11]. We 
would take the view that these findings represent reverse causation – whereby those 
with severe illness require insulin to treat stress hyperglycaemia. An alternative 
explanation is that the optimal glycaemic targets in patients with type 2 diabetes and 
severe illness are unclear, and some observational analyses have suggested more 
liberal targets in patients with Type 2 Diabetes may be preferable – a hypothesis being 
examined by the LUCID Randomized Controlled Clinical Trial [12].  
 
It is interesting to speculate on the pathophysiological mechanisms linking severity of 
respiratory failure to insulin requirements in viral pneumonitis. It is well established 
that acute illness causes stress hyperglycaemia and the production of pro-
inflammatory cytokines and counterregulatory hormones are likely key players in this 
process [13]. What is less well established is that severity of respiratory failure 
specifically is associated with insulin resistance and stress hyperglycaemia. Causative 
mechanisms likely overlap but some pathogenic processes may be specific to tissue 
dysoxia. Examining insulin requirements and glycaemia treated with liberal and 
conservative oxygen strategies in randomized controlled trials may be instructive in 
this regard.  
 
Our analysis is limited by its relatively small sample size and its single center nature. 
Further determination of the specific effects of COVID-19 infection as opposed to the 
effects of general critical illness will require collection of data from larger, well matched 
cohorts with other precipitating causes of stress hyperglycemia.  
It should be noted that we cannot exclude the existence of rare hyperglycemic 
syndromes triggered by SARS-CoV-2 infection. For example, our study cannot inform 
the etiological role of SARS-CoV-2 infection in autoimmune diabetes as has been 
studied in larger epidemiological analyses [14-16]. Large, registry-based studies (e.g. 
COVIDIAB registry) with prolonged follow-up will be required to study this and to 
determine the long-term effects of COVID-19 infection on glucose metabolism more 
broadly. 
In conclusion, high insulin requirements in severe COVID-19 likely relate to the 
severity of respiratory failure and the high prevalence of metabolic disease in patients 
with severe illness. When these factors are accounted for, insulin requirements are 
comparable to that seen in non-COVID-19 viral pneumonitis.  
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Legend 
Figure 1 – Insulin requirements of patients admitted to ICU with COVID-19  and 
non-COVID-19 viral pneumonitis. A) Tukey box plots of maximum cumulative insulin 
requirements in a single day in the complete cohort, P = 0.003 by Mann-Whitney U 
test. B) Tukey box plots of mean daily insulin dose day in the complete cohort, P =  
0.003 by Mann-Whitney U test C) Tukey box plots of maximum cumulative insulin 
requirements in a single day in the matched cohort, P = 0.46 by Wilcoxon signed rank 
test. D) Tukey box plots of mean daily insulin dose day in the matched cohort, P = 
0.52 by Wilcoxon signed rank test.  For clarity only insulin dose for patients receiving 
insulin plotted (i.e. no zero values plotted) but statistical tests are performed on the 
whole dataset. IU – International Units.  
Table 1 - Correlation coefficients ± standard error, multiple R-squared and P-values 
from multivariable linear regression analysis of maximum insulin requirement in a 











































































































Maximum insulin requirement in a single day, R2 = 0.47 
COVID-19 0.10 ± 0.71 0.89 
Diabetes Mellitus 4.66 ± 0.75 <0.001 
Respiratory Support 1.41 ±  0.21 <0.001 
Mean insulin requirements per day, R2 = 0.50 
COVID-19 0.20 ± 0.50 0.71 
Diabetes Mellitus 5.60 ± 1.05 <0.001 


















Supplementary Appendix  1 
The excess insulin requirement in severe COVID-19 compared to non-COVID-19 2 
viral pneumonitis is related to the severity of respiratory failure and pre-existing 3 
diabetes.  4 
Sam Lockhart, Harry Griffiths, Bogdan Petrisor, Ammara Usman, Julia Calvo-Latorre, 5 
Laura Heales, Vishakha Bansiya, Razeen Mahroof, Andrew Conway Morris 6 
 7 
Methods 8 
Study Centre 9 
All a ie  i cl ded i  he d  e e a aged i  Adde b ke  h i al i e i e 10 
care unit which includes a 20-bed general intensive care unit with a further 12 high 11 
and intermediate dependency beds which were repurposed as critical care beds as 12 
required during the pandemic, and a 27-bed specialist neurocritical care unit. 13 
 14 
Glycemic control  15 
Our departmental policy for management of hyperglycaemia in critical care advises 16 
commencement of a variable rate intravenous insulin therapy when two consecutive 17 
blood glucose readings are >10 mmol/L if there has been no recent (within 6 hours) 18 
hypoglycaemia. The rate of intravenous insulin infusion is adjusted by bedside nursing 19 
staff depending on blood glucose according to a standard prescription which can be 20 
titrated by medical staff with the aim of maintain a target blood glucose of 6-10mmol/L. 21 
In patients with persistent hyperglycaemia or high insulin requirements, subcutaneous 22 
basal insulin may be commenced under the advice of the specialist diabetes team. 23 
When this was added it was solely with the intention of improving glycaemic control. 24 
There was not, to our knowledge, any case where subcutaneous insulin therapy was 25 
used in an effort to spare syringe pumps during the COVID-19 pandemic.  26 
 27 
Data Collection  28 
Demographic data was manually collected from review of the participant electronic 29 
medical record. Admission values for cross sectional variables such as age and BMI 30 
were recorded. 31 
 32 
A diagnosis of pre-morbid diabetes mellitus was recorded if the patient was on any 33 
anti-hyperglycemic therapy, if they had a recorded diagnosis of diabetes mellitus in 34 
their problem list or if they had a pre-morbid HbA1c that was diagnostic of Diabetes 35 
according to World Health Organisation Diagnostic Criteria (48 mmol/mol or over). 36 
Diabetes mellitus was attributed to Type 2 Diabetes unless there was a positive 37 
diagnosis of Type 1 Diabetes recorded in the notes. Prior to admission hyperglycaemic 38 
therapy was documented according to the reconciled medications list in the electronic 39 
medical record and the medicines administration record was used to determine anti-40 
hyperglycaemic therapies used while in hospital. The discharge summary was used 41 
to determine antihyperglycaemic medications that were continued on discharge. 42 
Insulin doses recorded were the sum of all subcutaneous and intravenous insulin 43 
ad i i e ed d i g he a ie  a  i  i e i e ca e.  44 
 45 
Acute corticosteroid use was examined and the number of days that corticosteroids 46 
were administered was recorded. We did not include corticosteroid use that was 47 
prescribed regularly prior to admission.  48 
APACHE II scores were collected on admission to intensive care and were obtained 49 
from routinely collected audit data.  50 
Age, Sex, BMI (on ICU admission), obesity status and level of respiratory support were 51 
manually collected from the a ie  elec ic edical ec d b  ai ed 52 
investigators.  53 
Follow-up 54 
For glycaemia and insulin requirements, participants were followed up until they were 55 
discharged from ICU or died. Length of ICU stay is detailed in Supplementary Table 56 
3.  As noted in the main manuscript we had information on discharge medication on 57 
61/62 patients who survived to hospital discharge, the one patient we did not have 58 
information on was repatriated to their local hospital after completion of their ICU stay.  59 
Matching 60 
Patients admitted with COVID-19 pneumonitis were matched in a 1:1 ratio to a 61 
historical control cohort of patients admitted to ICU with non-COVID-19 viral 62 
pneumonitis. Subjects were strictly matched so that the level of respiratory support 63 
received (e.g. mechanical ventilation, neuromuscular blockade, epoprostenol therapy, 64 
prone ventilation and extra-corporeal membrane oxygenation) and diabetes status 65 
were identical. If there was more than one suitable match then age was used (as age 66 
was significantly associated with insulin requirements when added to the model 67 
presented in supplementary table 3), if age was similar (tolerance ± 5 years) then BMI 68 
was reviewed, if BMI was similar (tolerance ±2.5 kg/m2) then Sex was reviewed. These 69 
criteria were pre-specified prior to matching and undertaken blinded to knowledge of 70 
insulin requirements.  71 
 72 
 73 
Statistical analysis 74 
Continuous variables were assessed for normality by visual inspection of histograms 75 
of each variable and performing the Shapiro-Wilk  Te . S de  -test was used for 76 
comparing means of normally distributed data, Mann-Whitney U test and Wilcoxon 77 
Rank test were used for comparing unpaired and paired non-normally distributed data, 78 
respectively. All P-Values reported are from two-tailed tests.  79 
 80 
The level of maximum respiratory support required during the ICU stay was assigned 81 
an ordinal scale : 0  self ventilating, 1- mechanical ventilation, 2  neuromuscular 82 
blockade, 3  nebulized epoprostenol, 4  prone ventilation, 5  extracorporeal 83 
membrane oxygenation. The regression co-efficients and p-values reported are from 84 
a model encoding respiratory support as a continuous variable but a sensitivity 85 
analysis encoding respiratory support as a categorical variable showed similar results. 86 
For the purposes of analysis, the number of days receiving steroids was normalized 87 
according to the length of stay to avoid the confounding effects of duration of ICU stay. 88 
Insulin requirements (both maximum use in a single day and mean daily use) were 89 
right skewed and were squareroot transformed to facilitate regression analysis. For 90 
multiple regression analysis diabetes status and level of required respiratory support 91 
were included in the model as these two variables were unbalanced in the COVID-19 92 
and non-COVID-19 viral pneumonitis groups and were the most significant predictors 93 
of insulin requirement. The addition of age and BMI to the model (which were both 94 
significant in univariate analysis) did not improve the predictive ability of the model as 95 
assessed by a likelihood ratio test, nor did they alter the relationship between COVID-96 
19 and insulin requirement. 97 
 98 
The results reported are from linear regression analysis of the whole data set but 99 
similar results were observed (e.g. COVID-19 was not a significant predictor of insulin 100 
requirements after addition of an index of respiratory support and diabetes status were 101 
added to the model) using tobit regression with censoring at 0 or if insulin requirement 102 
was dichotomized to those requiring and not requiring insulin and analyzed by binomial 103 
regression. 104 
Statistical analysis was conducted using Graphpad Prism version 8.4.3 and R.  105 
Clinical Governance and Oversight  106 
As a retrospective analysis of anonymized, routinely collected data the requirement 107 
for ethical committee review and consent was waived, the evaluation was registered 108 
with the responsible healthcare organization (Cambridge University Hospitals NHS 109 
Foundation Trust).110 
Supplementary Appendix Figure 1 
 


















Supplementary Appendix Figure 2 
 
Supplementary Figure 2 – Glucose levels of patients of patients admitted to ICU with COVID-19  
and non-COVID-19 viral pneumonitis. A) Tukey Box plots of mean blood glucose in the complete 
cohort, P = 0.42 by t-test B) Tukey Box plots of percentage time in target range (4-10mmol/L) in the 
complete cohort, P = 0.27 by Mann-Whitney U test C) Tukey Box plots of mean blood glucose in the 
matched cohort, P = 0.39 by paired t-test. D) Tukey Box plots of percentage time in target range (4-



































































































) P = 0.39
Supplementary Appendix Table 1 
 
Beta R2 P-Value 
Maximum insulin requirement in a single day 
Age  0.08 ± 0.04 0.05 0.03 
Male -0.23 ±1.10 0.0004 0.83 
Type 1 Diabetes 7.58 ± 3.42 0.04 0.03 
Type 2 Diabetes  5.60 ± 1.05 0.23 <0.001 
BMI 0.19 ± 0.08 0.06 0.02 
APACHE II 0.19 ± 0.09 0.04 0.05 
Respiratory Support 1.64 ±  0.26 0.30 <0.001 
Steroid Exposure 1.37 ± 1.80 0.006 0.45 
Mean insulin requirements per day 
Age  0.04 ± 0.03 0.02 0.14 
Male -0.32 ± 0.82 0.02 0.70 
Type 1 Diabetes 6.34 ± 2.52 0.07 0.01 
Type 2 Diabetes  4.53 ± 0.75 0.29 <0.001 
BMI 0.16 ± 0.06 0.08 0.008 
APACHE II 0.12 ± 0.07 0.03 0.08 
Respiratory Support 1.10 ± 0.20 0.25 <0.001 
Steroid Exposure 1.33 ± 1.33 0.01 0.32 
 
Supplementary Table 1 – Correlation coefficients ± standard error, multiple R-squared and p-values 
from univariate linear regression analysis of maximum insulin requirement in a single day and mean 
insulin requirements per day, following a square root transformation. BMI – Body Mass Index, 








Supplementary Appendix Table 2 
Viral Isolate N 
Influenza A 21 
Influenza B 4 
Influenza H1N1 1 
Enterovirus 2 
Varicella Zoster Virus 1 
Cytomegalovirus 1 
Human Metapneumavirus 2 
Rhinovirus 3 
Parainfluenza 6 
Non-Typeble picornavirus 1 
Adenovirus 1 
No viral isolate – clinical diagnosis 5 
 
Supplementary Table 2 – Viral isolates in the Non-COVID-19 viral pneumonitis cohort.  
 
Supplementary Appendix Table 3 
 
Supplementary Table 3 – Demographics of patients with COVID-19 viral pneumonitis and non-COVID-19 viral 
pneumonitis in the whole cohort and in the cohort matched for diabetes status and severity of respiratory 
failure. Categorical variables are summarized as % (n) and continuous variables as median (Q1, Q3). BMI – Body 
Mass Index, APACHE II - Acute Physiology And Chronic Health Evaluation II, ICU – Intensive Care Unit, ECMO – 















Age 62 (50, 69) 62 (48.5, 68) 62 (49, 67.5) 62.5 (57, 68.25) 
Male 68% (63) 57% (56) 61.1% (22) 61.1% (22) 
Type 1 Diabetes 2% (2) 4% (2) - - 
Type 2 Diabetes 24% (22) 11% (5) 8.3% (3) 8.3% (3) 
BMI 28.5 (25.8, 32.4) 27.2 (24.7, 32.3) 28.5 (25.8, 31.2)  27.5 (25.8, 32.3) 
APACHE II 15 (12, 19) 17 (13.5, 20.5) 13.5 (11, 18) 16 (13.25, 20) 
Obesity 39% (36) 26% (12) 35.1% (13) 27.8% (10) 
Mechanical 
Ventilation 
83% (76) 67% (31) 61.1% (22) 61.1% (22) 
Neuromuscular 
Blockade 
72% (66) 33% (15) 36.1% (13) 33.3% (12) 
Epoprostenol 51%  (47) 15% (7) 19.4% (7) 19.4% (7) 
Proned 45.6% (42) 6.5% (3) 11.1% (4) 8.3% (3) 
ECMO 7% (6) 2% (1) 2.8% (1) 2.8% (1) 
Steroids 51.1% (47) 57.9% (29) 47.2% (17) 61.1% (22) 
ICU Survival 72.8% (67) 71.1% (32) 80.6% (28) 69.4% (25) 
Length of Stay (Days) 13 (7, 20) 5.5 (3, 14.75) 7 (4, 13) 5 (3, 14) 
Supplementary Appendix Table 4 
 
Supplementary Table 4 – Prior to admission diabetes therapies in patients with COVID-19 and Non-
COVID-19 viral pneumonitis (Non-COVID-19) as a percentage (n) of all patients with type 2 diabetes 
in each group. SU – Sulfonylurea, DPP4 – Dipeptidyl peptidase-4, GLP1RA – Glucagon-Like Peptide-1 























 Metformin SU  DPP4 GLP1RA SGLT2i TZD Insulin 
COVID-19 68.1% (15) 27.2% (6) 9.0% (2) 4.5% (1) 1 (4.5%) 0 36.4% (8) 
Non-COVID-19 80% (4) 20% (1) 0 0 0 0 40% (2) 
 
 
 
 
 
 
 
 
 
 
 
